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Abstract
Background: Biological molecular markers such as proto-oncogene erbB-2 (HER-2/neu, c-erbB-2), the CXC
chemokine receptor 4 (CXCR4), estrogen receptor (ER), Proliferating Cell Nuclear Antigen (PCNA), DNA
topoisomerase II (topo II), P-glycoprotein (P-gp) and glutathione S-transferase (GST) were observed for changes
after administration of neochemotherapy and whether these protein expression changes were correlated with
response to chemotherapy.
Methods: Sixty-four patients with primary breast cancer who had undergone neo-adjuvant chemotherapy were
enrolled in the present study. The expressions of C-erbB-2, CXCR4 and ER-a were measured by
immunohistochemistry (IHC) on full tissue sections and on tissue microarrays (TMAs). PCNA, TopoII, P-gp and GST
were measured by IHC on TMAs. On the other hand, CXCR4, C-erbB-2 and ER-a expressions were detected using
western blot analysis to 16 pairs of fresh preoperative core biopsies. The final surgical specimens were obtained from
patients with breast carcinoma who received neo-adjuvant chemotherapy and obtained a partial response (PR).
Results: Our data demonstrated that the levels of C-erbB-2, CXCR4 and ER-a in patients decreased after they
received neo-adjuvant chemotherapy on full tissue sections and on TMAs. The PCNA level was down-regulated
after receiving neo-adjuvant chemotherapy, and no significant change was observed for TopoII, P-gp and GST. The
levels of C-erbB-2, CXCR4 and ER-a were also down-regulated after neo-adjuvant chemotherapy was administered,
as detected by western blot. In addition, the change expressions of C-erbB-2 and CXCR4 in specimens tended to
be correlated with pathological change to neo-adjuvant chemotherapy on full tissue sections and on TMAs in a
Pearson chi-square analysis.
Conclusions: As demonstrated in our study, after breast cancer patients were treated with neo-adjuvant systemic
therapy, decreased expressions of C-erbB2, ER-a and CXCR4 were observed. Down-regulated expressions of c-erbB-
2 and CXCR4 may be a novel mechanism of chemotherapy; the changes of these objective markers may be useful
in evaluating the clinical response of neo-adjuvant chemotherapy in breast cancer.
Background
Chemotherapy is widely administered in the primary
treatment of breast cancer. However, a subset of patients
undergoing neo-adjuvant therapy suffers from side effects
without benefiting from treatment. Furthermore, in
patients with progressive disease, valuable time for
efficient treatment is lost. The only chance to improve
survival for breast cancer patients is to select timely,
aggressive, and optimal therapy at the time of diagnosis.
Any improvement in selecting patients who have a better
than average chance to benefit from a given chemother-
apy regimen is an important improvement over the
current unselected empirical use of various adjuvant che-
motherapy regimens. Given these facts, finding a method
to evaluate the response to neo-adjuvant chemotherapy
would be important. Molecular change may more
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accurately evaluate the effects of chemotherapy than a
method based on morphological change alone. This
study assesses whether some important biological mole-
cular markers such as C-erbB-2, CXCR4, PCNA, TopoII,
P-gp and GST changed after administration of neo-adju-
vant chemotherapy and whether these protein expres-
sions or change expressions were correlated with neo-
adjuvant chemotherapy.
Methods
Patients and clinical specimens
Sixty-four breast cancer patients who received neo-
adjuvant chemotherapy and underwent surgery between
January 2004 and September 2006 at the Breast Disease
Center, Southwest Hospital of Third Military Medical
University, Chongqing were included in this study.
Forty-eight pairs of core biopsies and final surgical
breast cancer specimens were formalin-fixed and paraf-
fin-embedded. The remaining 16 pairs of fresh preo-
perative core biopsies and final surgical specimens were
stored at a temperature of -80°C.
Treatment
Patients received CEF treatment (5-fluorouracil; epirubi-
cin; cyclophosphamide) or ET treatment (epirubicin and
Taxol) for one to six cycles (I-II stage for one- two cycles;
III-IV stage for three-six cycles). No patient received
tamoxifen as part of her neo-adjuvant treatment. Patients
were scheduled to undergo surgery after preoperative che-
motherapy with tumor excision and axillary node
dissection.
Tumor tissue microarrays (TMAs) construction
One TMA was constructed with 0.6 mm-diameter, single
punches from formalin-fixed, paraffin-embedded core
biopsies and surgical resection specimens of 48 patients
with breast cancer, using a tissue-arraying instrument
(Beecher Instruments®, Silver Spring, MD, USA). For each
tumor, two representative tumor areas were carefully
selected from a hematoxylin- and eosin-stained section of
a donor block. Core cylinders were punched from each of
these areas and deposited into a recipient paraffin block.
Consecutive 4 μm-thick TMA sections were cut and
placed on charged Poly-L-Lysine-coated slides for immu-
nohistochemistry analyses.
Immunohistochemical staining (IHC) of biomarkers
Immunohistochemistry analyses were performed using
DAKO the EnVisionTM IHC Detection System Kit as
described by Yang et al [1]. The primary antibodies used
were Monoclonal Mouse Anti-Human c-erbB2 (ZYMED
Co., USA), Monoclonal Mouse Anti-Human CXCR4
(Sigma), Monoclonal Mouse Anti-Human Estrogen
Receptor a (Gene Tech), Monoclonal Mouse Anti-Human
PCNA (Gene Tech), Mouse Anti-HumanTopoII a (Gene
Tech), Mouse Anti-Human P-gp (Gene Tech) and GST
(Gene Tech).
Evaluation of immunohistochemical staining
C-erbB-2 was localized in the cell membrane and was
scored semi-quantitatively using the following Food and
Drug Administration (FDA)-approved scoring system
[2]. For immunohistochemical staining of CXCR4, a
combination of membrane and cytoplasm staining was
observed in samples. The immunostaining score of
CXCR4 was calculated by the multiplication of the per-
centage of positive tumor cells (0–100) by the staining
intensity (grade 1–4), producing a total range of 0–400
[3,4]. Standard clinical factors such as ER-a, PCNA,
TopoII, P-gp and GST have been evaluated routine
methods in our test.
Western blot analysis
Approximately 40 µg of total protein was boiled in a load-
ing buffer for 5 minutes, subjected to electrophoresis
through a 4%–12% polyacrylamide gradient Tris-glycine
gel, along with Biotinylated Protein Ladder Detection Pack
(Cell Signaling Technology, Inc.), and electroblotted onto
a PVDF membrane (Dupont, USA). The Western Blotting
Chemiluminescence Regent Plus Kit (Mouse/Rabbit)
(ShangHai ShengNeng BoCai Biotechnology Co., Ltd.) was
used for the detection of proteins. The membrane was
briefly incubated for 1 hour at room temperature in 1%
blocking solution and for 1 hour at 4 °C in a dilution of
1:500 Rabbit anti-Neu antibody (185Kd, Santa Cruz
Biotechnology, Inc.) or ERa (66kDa, Santa Cruz Biotech-
nology, Inc.) or Rabbit anti-CXCR4 (43Kd, Affinity BioR-
eagents, ABR) and 1:1000 Mouse monoclonal Beta-actin
Antibody (42Kd, Novus Biologicals) in 0.5% blocking solu-
tion. The membrane was washed two times in PBS, and
then with Biotin-labeled secondary antibody in a dilution
of 1:2500 (Sigma, USA), incubated for 60 minutes at 4 °C,
and then anti-Biotin HRP antibody is applied and detected
with avidin conjugated to horseradish peroxidase (DAKO,
USA). All blots were scanned with the Image Quant soft-
ware using an electrochemifluorescence (ECF) Western
blotting detection system (LabworksTM Analysis Software,
USA).
Assessment response by pathological change and
physical examination
Pathologic response was classified according to Abrial et al
[5]. The clinical baseline and preoperative measurements
were obtained with a caliper by the same medical oncolo-
gist. Clinical responses were recorded according to the cri-
teria of International Union Against Cancer (UICC).
Pathologic response class 1-2 is equivalent to CR and class
3, 4 is equal to PR and SD, respectively.
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Statistical analyses
The tests of statistical significance in this study were deter-
mined by Pearson’s chi-square (c2) test and by Wilcoxon
signed-rank test. In all tests, P < 0.05 was considered as
statistically significant. All tests of statistical analyses were
performed using SPSS Statistical Software Version 18.0.
Results
Clinical outcome
Sixty-four patients who received primary chemotherapy
were included in the study. The tumor samples included
(56 of 64) 87.5% invasive ductal, (8 of 64) 12.5% invasive
lobular. The grade distribution was 24% grade 1, 40%
grade 2, and 36% grade 3. The average age of a patient was
47 years (range: 22–71); 51.56% (33of 64) of the patients
had lymph node-negative disease, while 48.44% (31of 64)
had lymph node-positive disease. After the administration
of a median of two courses of chemotherapy (range: 1-4),
the pathological response change class 1-3 (equal to clini-
cal CR and PR) [5] to primary chemotherapy was 41.7%
(20 of 48 patients). The pathological response class 1, 2,
and 3 was obtained in 4.2, 6.3, and 27.1% of the cases (1,
3, 15 of 48 patients, respectively). No PD under treatment
was observed. The median number of excised axillary
lymph nodes was 17.
Immunohistochemistry
The expression level of C-erbB-2 and the change was com-
pared between pre- and post-therapy samples by IHC on
TMAs (Figure 1) and full tissue sections (Figure 2, 1B and
2B). C-erbB-2 was found to be positive before and after
chemotherapy in 34.8%, 37.5% and 23.8%, 9.3% of the
patients, respectively. The results were determined to be
statistically significant (x2: 10.273, 13.201; p:0.00, 0.00,
respectively), as shown in Table 1. For the CXCR4
expression (Figure 2, 1C and 2C), 28 cases (72.51%)
showed positive staining with down-regulated expression
in 22 (56.4%) cases and up-regulated expression in 3 (7.6%)
cases, whereas 12 cases (28.2%) did not display any change
on full tissue sections. Overall, the expression levels of
CXCR4 were compared between pre- and post-therapy
samples by IHC on full tissue sections, where they were
found to be statistically significant (Z: -4.168, 3.331, p:
0.015, 0.00 by Wilcoxon signed-rank test). Correlation was
found for the change expressions of C-erbB-2 and CXCR4
on the two methods (r= 0.693, 0.457, p: 0.00, 0.001, respec-
tively, by Pearson chi-Squre). For the ER-a expression, 18
cases (37.5%) showed positive cytoplasm staining with
down-regulated expression in 12 (25%) cases and up-regu-
lated expression in 3 (7.6%) cases, whereas 27 cases
(56.25%) did not display change on full tissue sections
(Figure 2, 1D and 2D). The expression levels of ER-a were
compared between pre- and post-therapy samples by IHC
on full tissue sections. They were found to be statistically
significant (x2: 8.39; p: 0.040). After primary chemotherapy,
the percentage of cells expressing PCNA was significantly
reduced (pre-treatment versus post-treatment median
value: 43.63% versus 27.89%; p < 0.001 by Wilcoxon
signed-rank test). Interestingly, on a macroscopic level, not
only C-erbB-2, CXCR4 and ER-a positive stain cells were
eliminated, but membrane and cytoplasma stains were also
reduced after chemotherapy, as we observed. There were
no significant changes in the expressions of TopoII, P-gp
and GST before and after chemotherapy.
The analysis of expression levels of C-erbB-2, CXCR4, ER-a
between pre- and post-therapy samples with western
blots
The expression levels of C-erbB-2 were compared
between pre- and post-chemotherapy samples, western
Figure 1 H&E staining of a paraffin block section and enlarged image of tissue sample from tissue microarray A: H&E staining of a
paraffin block section (25 × 25 mm) from the TMA containing 192 arrayed samples, including 48 pairs of preoperative core biopsies and final
surgical primary breast cancer specimens. B: The enlarged image of representative tissue sample from a tissue microarray (10×10).
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blot results are shown in Figure 3. Table 2 details the
expression levels of C-erbB-2 that were found to be
down-regulated after administration of chemotherapy
(Z: -4.168, p: 0.012).
The changes of C-erbB-2, CXCR4, and ER-a expressions
with pathological response
Analyzed by IHC on full tissue sections and on TMAs
(Figure 4), the change expression of C-erbB-2 in speci-
mens tended to be correlated with pathological response
to neo-adjuvant chemotherapy (c2: 9.697 and 7.141,
respectively; p: 0.046 and 0.028, respectively). The
change expression in the response cases (pathological
response for stages I-III) was significantly higher than
the no response cases (pathological response for stage
IV). Decreased expressions of C-erbB-2 and CXCR4 in
specimens tended to be correlated with pathological
response to neo-adjuvant chemotherapy (r: -0.320,
-0.312; p: 0.027, 0.037, respectively) (Table 3). No corre-
lation was observed for change expressions of ER-a in
specimens with pathological response to neo-adjuvant
chemotherapy and on TMAs (r: -0.299; p: 0.073). No
correlation was observed between pretreatment C-erbB-
2, CXCR4, ER-a, PCNA, TopoII, P-gp and GST status
with pathological response to neo-adjuvant chemother-
apy on TMAs (r: -0.253, -0.008, -0.23, -0.029, -0.254,
0.182 and -0.140, respectively; p: 0.106, 0.972, 0.149,
0.909, 0.362, 0.571 and 0.605).
Discussion
Several studies have addressed the theory that gene
expression patterns might be able to predict the response
of a primary breast tumor to neo-adjuvant chemotherapy,
but according to Juliane et al., [6] neo-adjuvant che-
motherapy results in alterations in gene expressions, and
gene expression patterns cannot predict responses to neo-
adjuvant chemotherapy. Several studies have addressed
the hypothesis that the changes in the expression of some
biological markers, such as proliferation indices, proliferat-
ing cell nuclear antigen, expression of P-gp, and epidermal
growth factor receptor and CD34, might be a response to
primary chemotherapy in breast cancer [7-12]. Recently,
there were also reports that stated neo-adjuvant che-
motherapy also resulted in alterations in molecular mar-
kers such as estrogen and progesterone receptor (ER/PR)
protein expressions [13]. In this study, we attempted to
identify whether some important biological molecular
markers such as C-erbB-2, CXCR4, PCNA, TopoII, P-gp
and GST changed after patients received neo-chemother-
apy and whether the change in protein expression was
correlated with neo-adjuvant chemotherapy.
IHC on TMA offers a powerful tool to quickly evaluate
the clinical relevance of differentially expressed genes and
proteins [14]. TMAs may simultaneously test a large series
of tumor samples and test for the same condition. Our
study demonstrates that C-erbB-2 and CXCR4 protein
expressions in breast cancer detected by TMAs were high
concordance with that of the full sections, demonstrating
that reliable results could be obtainable in detecting
Figure 2 C-erbB-2, CXCR4 and ER-a expressions in human breast tumor tissues pre- and post-treatment sample Sample 1: Core biopsy
before treatment. 1A: H&E staining; 1B: C-erbB-2 positive staining; 1C: CXCR4 positive staining; 1D: ER-a positive staining. Sample 2: Excised
specimen following chemotherapy. 2A: H&E staining; 2B: C-erbB-2 weakly positive staining after chemotherapy; 2C: CXCR4 weakly positive
staining after chemotherapy; 2D: ER-a negative staining after chemotherapy. (Original magnification, 400×)
Table 1 Expression status of C-erbB-2 in pre-
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expressions of protein by TMAs. Evaluated by TMA, there
were no significant changes observed in the expressions of
TopoII, P-gp and GST after chemotherapy.
It was shown in this study that primary system che-
motherapy resulted in a significant decrease in the expres-
sions of C-erbB-2, CXCR4 and ER-a. Quddus [15] also
found HER-2/neu expression decreased after neo-adjuvant
chemotherapy was administered in patients with locally
advanced breast cancer. However, contradictory findings
have also been reported; for instance, in Tinari’s experi-
mental study [16], no significant change was observed for
the expression C-erbB-2 after neo-adjuvant chemotherapy.
It should be emphasized that a lack of standardization of
IHC assay renders different results. For example, Tinari
[16] regarded 0 and 1+ as negative. A large portion of the
changes in C-erbB-2 expression from stain + to - might
have been neglected when conducting the research. Weak
HER-2 expressions (score 1+) was observed in approxi-
mately 17 of 48 cases (35.4%) in our study. Weak HER-2
expressions should be considered when comparing expres-
sions for pre- and post-chemotherapy. We observed a
change of HER-2/neu status following treatment: after
patients were treated with chemotherapy, the C-erbB-2
positive stained cells were eliminated, and membrane
stains were also reduced (Figure 2), from positive to nega-
tive and from scores of 1+ to scores of 0.
IHC is a useful technique for visualizing proteins and for
localization, but its extremely difficult techniques for
quantifying results and comparing values—such as intra-
tumor heterogeneity, differences in specimen processing,
and technical variables—may contribute to the expression
changes of molecular protein statuses [15]. Western blot,
also a widely used analytical technique, contains an inter-
nal standard that allows for comparison between samples
and quantification of protein expressions. Western blot
may be a reasonable means to overcome technical vari-
ables such as intra-tumor heterogeneity. We detected
C-erbB-2, CXCR4, ER-a expressions using western blot
analysis and found that their levels down-regulated after
neo-adjuvant chemotherapy.
We analyzed the relationship between changes in the
expressions C-erbB-2, CXCR4 and ER-a with their patho-
logical change after chemotherapy. Our results show that
decreased expressions of C-erbB-2 and CXCR4 tended to
Figure 3 Western blot analysis: Expressions of C-erbB-2, CXCR4 and ER-a in breast cancer Fifty micrograms of total protein of tissue
lysates from various breast cancer tissue were resolved on 4–15% SDS–PAGE and subjected to western blot analysis using antibodies that
recognize phospho-specific C-erbB-2, CXCR4 and ER-a respectively. 1a-4b: 4 pairs of preoperative core biopsies and final surgical specimens. a:
preoperative specimens; b: postoperative specimens.
Table 2 Analyses of expression levels of C-erbB-2, CXCR4, ER-a/b-actin (IOD) between pre- and post-therapy samples
with western blotting
Parameters Pre-chemotherapy specimens Post-chemotherapy specimens Z p
C-erbB-2 0.546±0.182 0.442±0.142 -3.103 0.002
CXCR4 0.908±0.341 0.829±0.277 -2.689 0.002
ER-a 0.701±0.174 0.559±0.126 -3.516 0.00
* p<0.05, compared with post-chemotherapy specimens
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be correlated with pathological response to neo-adjuvant
chemotherapy. There was no correlation observed for
changes in the expression of ER-a in specimens with
pathological response to neo-adjuvant chemotherapy.
Overexpression of c-erbB-2 and CXCR4 in breast cancer
was considered a risk factor and was associated with the
shortest survival times. Our results showed that good
responders exhibited more down-regulation in c-erbB2
and CXCR4 expressions after receiving chemotherapy
than did the poor responders. These results raise the pos-
sibility that neo-adjuvant chemotherapy may have elimi-
nated c-erbB2 and CXCR4 positive tumor cells or/and
reduced membrane and cytoplasmic stains. This may be a
possible explanation for chemo-resistance following an
initial period of chemosensitivity [15].
After treatment of neo-adjuvant systemic therapy in
decreased expressions of C-erbB2 and CXCR4 in breast
cancer, the findings are also biologically plausible since
these functional proteins (i.e., apoptosis, invasion, metasta-
sis, drug resistance/metabolism, proliferation) may repre-
sent effect, sensitivity and resistance to chemotherapy.
Such information may be useful in evaluating the effective-
ness of therapy. It may help us to better understand the
molecular mechanisms of cancer metastasis and the
mechanism of chemotherapy in decreased expressions of
CXCR4 and C-erbB-2 which may be correlated with che-
motherapy. This result has an interesting clinical
implication, namely patients with decreased expressions of
CXCR4 and C-erbB-2 after administration of neoadjuvant
chemotherapy are the patients most likely to receive the
greatest clinical benefit from chemotherapy treatment.
A correlation of HER-2/neu amplification/over-expres-
sion and favorable response to neo-adjuvant chemotherapy
has been shown in clinical studies [17-19]. Tinari [16]
explained that the predictive value of HER-2 is not direct,
but rather dependent on the TopoII genes status. The
value of HER-2/neu status as a predictor of response to
anthracycline-based chemotherapy is still a matter of
debate [20-22]. These contrasting results provide a plausi-
ble functional link between some important protein change
expressions with chemotherapy response. The expression
of C-erbB-2 might reflect the effect of the drug. Decreased
levels of C-erbB-2 protein may result from down-regula-
tion of transcription, increased degradation, or allele dele-
tion, owing to the effects of anthracyclines [23]. The
decreased expressions of C-erbB-2 and CXCR4 in speci-
mens that tend to be correlated with pathological response
to neo-adjuvant chemotherapy may be explained in our
study, or at least in part. Not all breast cancer patients
respond in the same manner to chemotherapy, and the
down-regulated expressions of CXCR4 and C-erbB-2 after
primary chemotherapy may be a sensitive response to
treatment. The change expression of markers such as
C-erbB-2 and/or CXCR4 in breast cancer may reflect the
response to primary treatment with anthracyclines or other
drugs such as taxanes.
A validated chemosensitivity predictive or evaluated
method could be useful in deciding which treatment
may or may not be effective in patients with advanced
disease. There are a limited number of studies that have
addressed the significance of changes in biological mar-
ker expressions as a consequence of primary chemother-
apy in breast cancer.
This study suggested that decreased expressions of
c-erbB-2 and CXCR4 may be a novel mechanism of
Figure 4 A: Anti-C-erbB-2 staining. B: Anti-CXCR4 staining. C: Anti-PCNA staining. D: Anti- GST staining. E: Anti- P-gp F: Anti-ToP staining. 1: Pre-
chemotherapy core biopsy breast cancer specimens; 2: Post-chemotherapy (at the time of surgery) surgical breast cancer specimens. (Evision+TM
System×100).
Table 3 Relation between the change of CXCR4
expression with pathological response in tumor tissue




Increased Decreased Unchanged c2 R p
Class 1-3 1 2 9
Class 4 2 21 10 8.03 -0.312 0.037
Pathologic response class 1-3 equals to Clinical responses (CR) and Pathologic
response (PR), class 4 equals to SD.
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chemotherapy; the changes of these objective markers
may be useful in evaluating the clinical response of neo-
adjuvant chemotherapy and selecting chemotherapy
regimen for postoperative chemotherapy in breast can-
cer. Our results provide, for the first time, clear evidence
that reduced or stable expressions of c-erbB2 and
CXCR4 after combination chemotherapy may be an
important factor to treatment. According to our results,
if decreased CXCR4 and HER-2 expressions are present
in a tumor, treatment could be continued, whereas
absence of change or increased CXCR4 and HER-2
expressions would imply that patients should be treated
with another chemotherapeutic regimen. If changes in
c-erbB2 and CXCR4 expressions are confirmed as being
associated with clinical survival in patients in operable
breast cancer, then these may be useful objective
response markers to evaluate the clinical response of
neo-adjuvant chemotherapy and select the appropriate
chemotherapy regimen for postoperative chemotherapy.
It will be important to further evaluate this concept in
future studies. Owing to the limited number of patients
and the retrospective nature of this study, large, pro-
spective studies are warranted to validate the observa-
tions from this study.
Conclusions
As demonstrated in our study, after breast cancer patients
were treated with neo-adjuvant systemic therapy,
decreased expressions of C-erbB2, ER-a and CXCR4 were
observed. Down-regulated expressions of c-erbB-2 and
CXCR4 may be a novel mechanism of chemotherapy; the
changes of these objective markers may be useful in evalu-
ating the clinical response of neo-adjuvant chemotherapy
in breast cancer.
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